cancer vaccine - Search News

Moderna’s cancer vaccine clears phase 3

Why Moderna’s Cancer Vaccine Is a Breakthrough for mRNA

The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate for melanoma in a final-stage trial is a watershed moment for cancer vaccine ...

· 1d · on MSN

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Nature · 2d

Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments?

· 23h

Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial

Participants in the clinical study of their new mRNA-based treatment experienced a 49% reduction in melanoma recurrence or death.

· 1d

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

· 1d

Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead

· 1d

Moderna’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

Ultragenyx notched its first gene therapy approval Wednesday when the FDA granted accelerated approval to Genglycos, the first approved treatment for glycogen storage disease type Ia, also known as Vo...

· 2d

Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough

· 1d

Moderna, Merck develop vaccine that could help fight against melanoma

2don MSN

Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Personalized Vaccine Helped Melanoma Patients Stay Cancer-Free Longer, Drugmakers Say

By Ellyn Vohnoutka HealthDay ReporterTHURSDAY, Aug. 20, 2026 (HealthDay News) — An experimental vaccine kept melanoma from returning or spreading in people at high risk of the skin cancer coming back, drugmakers Moderna and Merck announced Wednesday.

MedPage Today

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

Adding the cancer vaccine intismeran autogene to pembrolizumab (Keytruda) significantly improved recurrence-free survival and distant metastasis-free survival in a phase III trial of completely resected melanoma, Merck and Moderna announced.

Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)

The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of

Moderna's cancer vaccine hits key goal in melanoma trial with NYU Langone link

Moderna shares jumped this week after the company announced encouraging results from a late-stage melanoma trial.

Cleveland team develops cancer vaccine using COVID immunity

University Hospitals and Celloram are advancing Protexi, a platform that redirects antiviral immune memory from COVID-19 toward fighting tumors, with sarcoma trials planned.